Introduction
Epidermal growth factor is a 53-amino acid (molecular weight 6045d) polypeptide which is mitogenic for epithelial cells [1, 2] .
Since its discovery in 1962 [3] the relationship between EGF and tumor cell proliferation has held the attention of several scientific teams. Our own staff has been active in this field since 1982, reporting consecutively that high-affinity EGF-R are present in human breast cancer cells [4] , that the presence of EGF-R is inversely related to survival [5] and to the presence of estrogen receptors [6] , that expression of EGF-R is higher in metastasis than in primary tumors [7] , and that expression of EGF-R is frequently associated with expression of Transforming Growth Factor alpha [8] in what could be an autocrine loop.
Simultaneously, other groups have been reporting the overexpression of EGF-R in human tumors in diverse localizations such as lung [9] , prostate [10] , head and neck [11] , ovarian [12] and digestive tract [13, 14] .
Several attempts have been made using monoclonal antibodies (MoAb) against EGF-R for the treatment of tumors [15] [16] [17] .
Radioactive anti-EGF-R MoAb do localize in human tumors [15, 16] , but the therapeutic effect of naked anti-EGF-R MoAbs has been marginal up to now.
An alternative approach is EGF deprivation through active immunization, if tolerance against self-EGF can be broken. We have recently shown that this is possible [18] , and that antibodies against autologous EGF can be produced in mice and monkeys when the latter are immunized with self-EGF linked to a carrier protein or with EGF of another species.
Moreover, we have also shown that mice with antibody titers against self EGF have an altered biodistribution of EGF and also have better survivals when transplanted with Ehrlich Ascites Tumor cells [18] .
In the present paper we report the results of a pilot clinical trial in which patients with advanced-stage tumors were immunized with human recombinant EGF chemically linked to either TT or to P64k.
Patients and methods

Eligibility criteria
Patients with histologically-proven malignant carcinoma at advanced clinical stages were eligible. All patients had active progressing disease after failure of conventional treatment, and were not eligible for any other modality of onco-specific therapy. Their last onco-specific treatments had occurred at least four weeks prior to their inclusion in this protocol.
Other eligibility criteria were age between 18 and 75 years, WHO
Immunogenicity of the EGF vaccine
Antibody titers against self-EGF showed a significant increase after vaccination in 60% of the patients. This figure was the same for patients immunized with hu-EGF linked to tetanic toxoid and with hu-EGF linked to P64k (Table 1) . Antibody titers were more than 80% suppressed if EGF (0.1 ug/ml) was added to serum samples, indicating the specificity of the antibody measurement.
Patients immunized with the EGF-P64k preparation showed lower antibody titers against the carrier protein than those immunized with EGF-TT (Table 2a, b) .
Peak values of anti-EGF antibodies were obtained between days 21 and 28 after first immunization and decreased thereafter. The two carrier proteins showed similar kinetics (Figure la, b) .
We also compared antibody responses obtained in humans with those obtained in monkeys immunized with the same vaccine preparation and on the same vaccination schedule. When the EGF-TT preparation was used, humans showed lower anti-EGF antibody titers (geometric mean 1:1,320) than monkeys (geometric mean 1:14,142), but humans showed higher anti-TT antibody titers (1: 527,803) than monkeys (1:150,000). When the EGF-P64 preparation was used, antibody response in humans was lower than in monkeys against both the EGF (humans 1: 631, monkeys 1:14,142) and the carrier protein (humans 1:1,320, monkeys 1: 31,623).
Antibody titers against both EGF and carrier protein were in all patients IgG. No IgM class response was detectable.
Sera from the patient who achieved the highest antibody titers against EGF (patient 6 in Table 1 ), inhibited by 95% the binding of radioactive EGF to its membrane receptor.
Lymphocyte subpopulations (CD3, CD4, CD8) were counted before and after vaccinations, but no relationship between these data and the antibody response could be demonstrated in this small series.
Toxicity and clinical evaluation
Secondary reactions were very mild and limited to erythema and itching at the site of injection, and it disappeared without medication.
The hematological data (hemoglobin concentration, leukocyte and platelet counting) and the blood chemical data (glutamic -oxalacetic and glutamic -piruvic transaminases, alkaline phosphatase, and creatinin) also remained within normal ranges during the immunization and follow-up period. The clinical outcome of each patient is detailed in Table 3 .
Base-line antibody liter in healthy people
The measurement of some level of antibody titer against self-EGF in serum before immunization prompted us to cheeck this in a normal population sample. It was found Numbers are antibody titers (defined as the maximal sera dilution which, by the ELISA test, produced an optical density higher than that of the negative control (PBS) plus five standard deviations). Each serum was tested in triplicate. a Those measurements in which antibody titers at least doubled after vaccination. Numbers are antibody titers (as defined in Table 1 ). Each serum was tested in triplicate. " Those measurements in which antibody titers at least doubled after vaccination.
that sera from healthy blood donors contained measurable titers of antibodies against self-EGF in 61% of cases. These antibodies were EGF-specific in the sense that they could be more than 80% adsorbed by the addition of EGF to the serum at a concentration of 0.1 ug/ul.
On the other hand, only 9% of serum samples contained antibodies against insulin and 17% against serum albumin. These natural autoantibodies against self-EGF were also IgG class.
Discussion
To our knowledge, this is the first report of an attempt to induce an antibody response against self-EGF in human beings. An arbitrary unit was defined as the amount of antibody which, in our ELISA system, produces an optical density equal to that of the internal standard. The internal standard was serum from a previously immunized monkey, diluted 1:40,000. Each line in the figure represents data from a different patient. Each is the mean of triplicate measurements.
In the interest of simplicity, standard deviations are not included, but they were consistently below 10% of the mean value.
In this trial, immunization with human-recombinant EGF linked to a carrier protein elicited an increase in antibody titers against self-EGF in 60% of patients, which reached peak values 3-4 weeks after immunization and decreased thereafter.
The use of tetanic toxoid as carrier protein somehow 'deviates' the immune response, eliciting many more antibodies against the carrier than against EGF, as is to be expected, since all patients have at some time in their lives had anti-tetanic vaccinations.
The use of P64k protein of Neisseria meningitidis as carrier protein yielded a different antibody profile, with titers against the carrier P64k protein closer to those against EGF. This is probably because patients had not previously been exposed to Neisseria meningitidis.
The antibody response against both EGF conjugates in monkeys is in accord with this interpretation. The fact that patients before immunization (and also normal donors) had some measurable titer of IgG antibodies against self-EGF (but not against self insulin), is very interesting. It has been shown that natural autoantibodies do not recognize self proteins randomly, but are directed to a biased subset of self proteins [23] , and based on this fact it has been speculated that a kind of 'immunological homunculus' exists, integrated by self molecular components which are overexpressed in the pattern of recognition of antural autoantibodies [24] , although its physiological relevance is unknown. Epidermal growth factor could be connected to this part of the immune system.
The advanced clinical stage of patients included in this pilot trial precluded a long-term follow-up. However, during the observation time (range 2-6 months) there was neither clinical nor laboratory evidence of toxicity. Except for minor local itching and erithema, the vaccination procedure was very well tolerated.
It should be noted that there was no evidence of skin or mucous membrane toxicity. The lack of toxicity of Clinical stabilization up to month 5; hepatic metastases appeared; still alive on month 6
Pulmonar metastases appeared: still alive on month 6
Died on month 4: progression of primary lesion Died on month 6: clinical and radiologic stability up to month 5 EGF-immunization in adult animals has been previously reported [21, 22] , but this should be re-evaluated in more intensive immunization protocols. The evaluation of antitumor activity was not the goal of this trial, nor were objective remissions to be expected with any procedure at such advanced stages. No reductions in size of tumor lesions were recorded. However, most patients experienced subjective clinical improvement after vaccination and during the time when anti-EGF antibody titers were present.
In conclusion, vaccination with self EGF linked to a carrier protein is feasible, safe and immunogenic in humans. As this procedure has anti-tumor activity in animals [22] , it deserves more extensive clinical evaluation testing higher doses and more effective adjuvants in patients at less advanced clinical stages.
